The out-licensing agreement will result in Hyphens Pharma receiving an upfront fee and customary royalties on sales.

Pharma faces regulations and stringent rules for transparency, but the payoff is drugs that can get to market faster and ...

Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that it has granted the rights to commercialise its innovative product, Cerapro® MED Skin Barrier ...

Major pharmaceutical companies are pushing ahead with sweeping price increases on hundreds of medicines in the United States, ...

Johnson & Johnson’s $14.6 billion buyout of Intra-Cellular in the first mo | Of the top 10 biopharma M&A deals of 2025, six ...

It’s been another whirlwind year in the world of pharma marketing. | Updates on DTC advertising and DTP programs, as well as special reports, event coverage and, of course, news bulletins from the ...

While Novartis secured the biggest deal of the fourth quarter, a handful of riveting tales emerged from the bottom of the M&A ...

Liven Pharma Limited has entered into preliminary discussions with Hoover Pharma (Private) Limited regarding a “possible ...

Asahi Kasei Pharma Corporation has announced plans to relocate its R&D hub from Izunokuni City, Shizuoka Prefecture (Ohito) ...

Semaglutide patent expiries in India, Canada, and Brazil are poised to unlock over Rs 50 billion in revenue for generic ...

A parliamentary panel’s recent criticism of India’s drug price control mechanism has kept industry circles buzzing as the ...

Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher— here's why.